Introduction {#S1}
============

Acute lymphoblastic leukemias (ALLs), neoplasms of lymphoid precursors of the T and B cell lineages, are variably curable based on age of presentation, disease burden at diagnosis, immunophenotype, and cytogenetic abnormalities ([@R53]). Genomic aberrations detected by standard karyotypic analyses involve large chromosomal rearrangements (such as translocations), aneuploidy, and the gain or loss of large chromosomal regions. The advent of high throughput genomic technologies changed our view of leukemias, however, by showing that large numbers of more subtle genetic abnormalities are present in tumor cells. Key genes such as *PAX5* and *IKZF1*, important for normal lymphoid lineage commitment, are altered in ALL, often by copy number variations (CNV) such as deletion or amplification rather than translocation ([@R12], [@R41], [@R42], [@R43], [@R44]). Nevertheless, genetic aberrations that trigger the initiation of lymphoid leukemias and lymphomas other than the balanced translocations involving immunoglobulin and T cell receptor genes remain largely unknown.

In mice, retroviral insertion is a powerful strategy to identify genes implicated in the initiation of leukemia ([@R1], [@R19], [@R27], [@R62]). In certain inbred strains, the somatic insertion of retroviruses may activate expression of nearby proto-oncogenes or disrupt tumor suppressor genes. In these mouse tumors, **[c]{.ul}**ommon proviral **[i]{.ul}**nsertion **[s]{.ul}**ites (CIS) identify loci involved in the onset and progression of hematologic malignancies. We previously showed that mouse lymphoid malignancies containing retroviral insertions at the CIS designated **[e]{.ul}**cotropic **[v]{.ul}**iral **[i]{.ul}**nsertion site 32 (*Evi32)* had very high expression of the **[P]{.ul}**RDI-BF1 **[R]{.ul}**IZ homology domain (PR) **[d]{.ul}**o**[m]{.ul}**ain gene *Prdm14,* implicating this gene in the pathogenesis of mouse lymphoblastic leukemia (LL) for the first time ([@R11], [@R67]).

Prdm14 (human ortholog PRDM14) is a member of the PR domain-containing family of transcription factors, which are crucial for normal hematopoiesis and can behave as tumor suppressors or as proto-oncogenes ([@R16], [@R26], [@R31], [@R32]). While the molecular function of PRDM14 is largely unknown, sequence homology analyses suggest it may have histone methyltransferase (HMT) activity, similar to other PRDM family members ([@R2], [@R22], [@R30], [@R45], [@R50]). PRDM14 contains an N-terminal PR domain followed by six DNA binding C2H2 zinc fingers (ZF) ([@R16]). The PR domain is similar to the [S]{.ul}u(var)3--9, [e]{.ul}nhancer of zeste \[E(z)\], and [t]{.ul}rithorax (SET) domain, which has global HMT activity.

Expression of *Prdm14* is normally restricted to pluripotent cells. In embryonic stem (ES) cells, PRDM14 suppresses the expression of molecular markers associated with differentiation ([@R65]). PRDM14 mediates pluripotency in human ES cells by directly binding the proximal enhancer of the key pluripotency gene *POU5F1* (*OCT3/4*) ([@R7]). *Prdm14* is also expressed in primordial germ cells (PGCs) of mouse embryos from embryonic day (E) 6.5 until E 14.5, when it is required to establish the pluripotency of nascent PGCs by epigenetic reprogramming. As a result, mice with a null mutation of *Prdm14* fail to develop germ cells and are infertile ([@R35], [@R68]).

In addition to its normal role in resetting pluripotency, PRDM14 has oncogenic activity with overexpression correlating with early stages of breast cancer. Importantly, expression of PRDM14 reduced the chemosensitivity of cultured cancer cells and enhanced their proliferation, while siRNA-mediated knockdown of gene expression augmented their chemosensitivity ([@R47]). Furthermore, the 8q13.3 region containing *PRDM14* is amplified in 34--75% of human breast cancers ([@R39], [@R47]).

Given the oncogenic potential of this pluripotency gene in mouse and human malignancy, we investigated the possible contribution of *Prdm14* as an oncogene in mouse bone marrow (BM)-derived hematopoietic cells. Prior to leukemic transformation, overexpression of *Prdm14* caused a dramatic developmental shift characterized by expansion of pre-leukemic cells that share an immunophenotype with common lymphoid progenitors (CLP). Preleukemic and leukemic cells with dysregulated *Prdm14* overexpressed markers of stem cells and activators of oncogenic pathways. Thus, Prdm14 may initiate leukemia in a manner consistent with its role in the epigenetic regulation of pluripotency.

Results {#S2}
=======

Expression of *Prdm14* in mouse hematopoietic cells {#S3}
---------------------------------------------------

The coding sequence of *Prdm14* was subcloned into the [M]{.ul}urine Stem Cell Virus [I]{.ul}nternal Ribosomal Entry Site [G]{.ul}reen Fluorescent Protein [R1]{.ul} (MIGR1) retroviral vector ([Figure 1a](#F1){ref-type="fig"}) followed by an internal ribosome entry site (IRES) for co-translation of green fluorescent protein (GFP) to permit tracking of transduced cells. The same MIGR1 empty vector (EV) without *Prdm14* was used as a control. BM cells from 5-fluorouracil (5-FU)-treated CD45.2 mice were infected with each retrovirus ([Figure 1b](#F1){ref-type="fig"}). Lethally irradiated CD45.1 mice were reconstituted with the transduced cells, allowing for the identification of donor cells with antibodies specific for CD45.2 and transduced cells by GFP fluorescence. Northern blot analyses identified *GFP* and *Prdm14* transcripts of expected sizes, although *GFP* transcripts expressed from the *Prdm14*-MIGR1 vector were present at lower levels than those from the control vector in cells transduced with equivalent multiplicities of infection (MOI) ([Figure 1c](#F1){ref-type="fig"}). Successful engraftment of CD45.2^+^ donor cells was observed at four weeks after reconstitution ([Figure 1d](#F1){ref-type="fig"}). However, the frequency and fluorescence intensity of GFP^+^ cells in the peripheral blood (PB) of *Prdm14*-MIGR1 recipients were lower than for EV-MIGR1 recipients ([Figure 1d](#F1){ref-type="fig"}).

Overexpression of *Prdm14* causes skewing of lymphoid progenitor cell populations {#S4}
---------------------------------------------------------------------------------

Recipients of *Prdm14*-MIGR1 or EV-MIGR1-transduced BM cells were examined at four, eight, and twelve weeks after transfer to evaluate effects on hematopoiesis. Studies of recipient BM cells obtained at four weeks after reconstitution showed that although the frequencies of GFP^+^ cells were generally comparable for recipients of either transfected population ([Figure 2a](#F2){ref-type="fig"}, left panels), they differed drastically in immunophenotype. The BM of normal mice contains a small population of cells (\~0.02% of total BM cells) termed common lymphoid progenitors (CLP) ([@R34]) that do not express lineage-specific markers of mature hematopoietic cells (lin^−^) but express the IL-7 receptor alpha chain (IL-7Rα), the Kit receptor tyrosine kinase (c-Kit, CD117), and Sca1 (Ly6a). The BM of *Prdm14* recipients had a population of early lymphoid progenitor (IL-7Rα^+^lin^−^) cells that was over 30-fold greater than in EV recipients ([Figure 2a](#F2){ref-type="fig"}). IL-7Rα^+^lin^−^ cells expressing both Kit and Sca1 at high levels were also 15-fold more frequent in *Prdm14* recipients ([Figure 2a](#F2){ref-type="fig"}), with the great majority of cells being clearly Kit^+^ while expressing Sca1 at intermediate levels. Data from multiple mice indicate that the BM of *Prdm14* recipients had a dramatically expanded population of these early lymphoid and CLP-like cells four weeks after reconstitution, ranging from 3 -- 12% of the transduced BM population, a frequency 250--1000-fold greater than in EV recipients ([Figure 2b](#F2){ref-type="fig"}). This expansion was specific to the GFP^+^ *Prdm14*-expressing subset of cells in these mice; both the GFP^−^ population and BM from EV recipients contained only rare early lymphocyte progenitors and CLPs ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

The percentages of IL-7Rα^+^lin^−^ and Kit^hi^Sca1^hi^ cells among GFP^+^ cells in *Prdm14* recipient BM was lower in mice examined at twelve weeks after reconstitution than those evaluated at four weeks ([Figure 2c](#F2){ref-type="fig"}), although the magnitude of difference for the IL-7Rα^+^lin^−^ population compared to that for EV recipients was still quite high at 26.5-fold. At this time point, 25% of GFP^+^ cells in *PRDM14* recipient BM were lin^+^, in keeping with significant increases in both the BM and PB of cells expressing B220, a marker expressed by B lineage cells from the pre-pro-B to mature B cell stages of differentiation. The proportions of B220^+^ cells were significantly lower in *Prdm14* recipients at four and eight weeks after reconstitution, but were higher in BM at twelve weeks ([Figure 2e](#F2){ref-type="fig"}). The proportions of B220^+^ cells in PB were significantly higher for *Prdm14* recipients at all time points examined ([Figure 2e](#F2){ref-type="fig"}).

We then determined if the altered B220^+^ BM populations were comparable for all stages of B cell differentiation in the BM. FACS analyses of B cell subsets at four weeks after reconstitution with *Prdm14*- or EV-transfected cells revealed no significant differences in the cell populations at any stage of differentiation ([Figure 2f](#F2){ref-type="fig"}). At 12 weeks, however, the populations of pre-pro-B, pre-B and immature B cells were significantly reduced, and the proportions of pro-B cells were significantly increased in BM of *Prdm14* recipients compared to EV recipients ([Figure 2f](#F2){ref-type="fig"}). These findings indicated that the dominant CLP-like population, present at four weeks in the BM of *Prdm14* recipients, had undergone differentiation within the B cell lineage by 12 weeks after reconstitution, but that there was a relative block in maturation at the pro-B to pre-B transition. Consistent with the findings of a biased maturation within the B cell lineage, transduced cells from *Prdm14* recipients exhibited reduced myelo-erythroid developmental potential ([Supplementary Figure 2a, b, c](#SD2){ref-type="supplementary-material"}). Furthermore, *Prdm14*-transduced cells were less likely to contribute to thymic and peripheral T-cells ([Supplementary Figure 2d, e](#SD2){ref-type="supplementary-material"}).

Mice transduced with *Prdm14* develop LL {#S5}
----------------------------------------

One hundred three *Prdm14* recipient mice and 74 EV recipient mice were followed for up to one year after reconstitution. Beginning as early as 100 days after BM transplantation, *Prdm14* recipients developed labored breathing, lethargy, cachexia, hind limb paralysis, and kyphosis, ultimately progressing to death. By 52 weeks, 80% of the *Prdm14* recipients had been euthanized when moribund or had died compared to only 12% of EV recipients. Notably, 96% (69/72) of female recipients had died by one year after reconstitution compared to only 42% (13/31) of male recipients ([Figure 3a](#F3){ref-type="fig"}). At necropsy, almost all moribund *Prdm14* recipients had splenomegaly, with lower frequencies exhibiting lymphadenopathy, hepatomegaly, enlarged thymi, and PB lymphoblasts ([Figure 3b](#F3){ref-type="fig"}).

Analysis of slides stained with H&E prepared from tissues obtained at necropsy showed that all moribund *Prdm14* recipients died with LL involving the spleen and lymph nodes and often associated with involvement of the thymus and BM ([Figure 3d](#F3){ref-type="fig"}). Diagnoses of overt leukemia were based on the presence of lymphoblasts in hepatic blood vessels as well as blasts seen in PB. Hyperactivity of splenic red pulp elements was evidenced by expanded populations of megakaryocytes in about 17% of cases (data not shown) but without established features of megakaryocytic leukemia ([@R20]). Erythroblastosis was found in a small number of other cases. In contrast, moribund EV recipients had no evidence of LL or proliferative expansions of other lineages.

Clonality of the LL was confirmed by the detection of clonal proviral insertions and immunoglobulin (Ig) and T-cell receptor (TCR) rearrangements by Southern analysis. In addition, qPCR analyses showed that the tumors overexpressed *Prdm14* ([Figure 3c](#F3){ref-type="fig"}). Furthermore, syngeneic mice injected intraperitoneally with tumor cells from *Prdm14* recipients rapidly succumbed to leukemias that were clonally identical to the parental tumors ([Supplementary Figure 3a](#SD3){ref-type="supplementary-material"}).

The histopathologic diagnosis of LL is consistent with the origins of tumors from thymic T cells, BM-derived precursor B cells, or more mature peripheral B cells ([@R40]). To discriminate among these possibilities, DNA prepared from the tumors was examined by Southern blotting for the organization of Ig heavy chain (IgH) and Ig kappa light chain (IgK) gene segments. The results of these studies showed that 65% of evaluated malignancies had clonal rearrangements at the IgH locus, but none had IgK rearrangements ([Supplementary Figure 3b](#SD3){ref-type="supplementary-material"} and data not shown). This indicated that the tumors with clonal IgH rearrangements were arrested at the pro-B cell stage of differentiation, which is characterized by V(D)J rearrangements at IgH with the IgK locus in germline configuration. Studies of the same DNAs revealed that 12% of the cases had clonal rearrangements at the TCR Jβ1 or Jβ2 loci, indicating a T-cell origin ([Supplementary Figure 3c](#SD3){ref-type="supplementary-material"} and data not shown). Co-existing clonal rearrangements of IgH and TCR loci were identified in 19% of cases, indicating the presence of composite tumors comprised of distinct neoplasms of T and B cell origin, B lineage tumors that have undergone non-productive rearrangements at TCR loci, or T lineage tumors with DJ only rearrangements in IgH. Of note, one tumor had no Ig or TCR rearrangement but was classified as LL by histopathology.

Flow cytometric studies showed that the LL expressed cell surface markers characteristic of lymphoid progenitors, B-cells, or T-cells, consistent with lineage assignments inferred from clonal rearrangements of Ig and TCR loci. The percentages of GFP^+^ tumor cells in BM, thymus, blood and peripheral lymphoid tissues ranged from \~40% to \>95% of all WBCs ([Figure 4a,b,c](#F4){ref-type="fig"} and data not shown). Most tumors analyzed were B220^+^, indicative of origins from B lineage cells. More detailed analyses indicated that the B220^+^ tumors were arrested at different stages of early B cell development including CD19^−^ CD43^+^IgM^−^ pre-pro-B cells as well as CD19^+^CD43^+^IgM^−^ pro-B cells ([Figure 4a](#F4){ref-type="fig"}). BM and thymi from mice that developed T-lineage tumors were populated by CD4^+^CD8^+^ cells similar to the "double-positive" population found in normal thymus but not in spleen ([Figure 4b](#F4){ref-type="fig"}). Notably, all LL with thymic involvement carried clonal TCR rearrangements, and were classified as either pre-T-cell or mixed tumors by molecular rearrangements. One LL examined by flow cytometry was lin^−^ but expressed IL-7Rα and Kit at high levels and Sca1 at intermediate levels ([Figure 4c](#F4){ref-type="fig"}), a phenotype like that of normal CLPs ([@R34]).

Expanded CLP-like cells and tumors in Prdm14-transduced mice express genes associated with pluripotency, early B-cell development, and oncogenesis {#S6}
--------------------------------------------------------------------------------------------------------------------------------------------------

In order to determine downstream effects of Prdm14 expression, populations of CLP-like cells (IL-7Rα^+^lin^−^Kit^+^Sca1^+^) were isolated from *Prdm14*-transduced and EV-transduced mice at four weeks post transplantation, and examined for transcript profiles using microarrays. 1450 genes were differentially expressed (p ≤ 0.05) between the two groups. Of genes with fold change differences of 1.5 and higher, 284 were upregulated and 125 were downregulated in CLP-like cells from *Prdm14*-transduced mice ([Supplementary Table 1](#SD8){ref-type="supplementary-material"}). Correlation of differential expression distinguished between Prdm14-transduced and EV-transduced IL-7Rα^+^lin^−^Kit^+^Sca1^+^ cells ([Supplementary Figure 4](#SD4){ref-type="supplementary-material"}). Gene ontology and pathway analyses of differentially expressed genes revealed genes involved in early B-cell lineage commitment; regulators and mediators of Wnt, AKT, and Ras pathways; epithelial-to-mesenchymal transition; and previously well-characterized oncogenes ([Figure 5a](#F5){ref-type="fig"}). Strikingly, a number of the transcripts distinguishing the two cell populations examined were for genes or non-coding RNAs that are regulated by imprinting. Both maternally and paternally imprinted genes were overexpressed, including genes expressed from the same locus such as *Dlk1* and *Meg3* (*Gtl2*). Downregulated genes included signal transduction kinases and B-cell activation genes ([Figure 5a](#F5){ref-type="fig"}).

Data from gene expression profiles of selected genes in individual splenic tumors from Prdm14-transduced mice showed sustained upregulation of imprinted genes such as *Meg3* and *Dlk1*. Strikingly, additional genes were upregulated in tumors, including the pluripotency gene *Pou5f1* and *Prdm14*'s PGC partner *Prdm1* ([Figure 5b](#F5){ref-type="fig"}). *Myb* was highly expressed in *Prdm14*-induced LLs, but not in pre-leukemic cells ([Figure 5b](#F5){ref-type="fig"}). Myb protein was also upregulated in tumors compared to pre-leukemic cells overexpressing *Prdm14* ([Figure 5c](#F5){ref-type="fig"}). *Sox2* was downregulated, but other pluripotency genes (*Nanog*) and early B-cell genes (*Pax5, Ebf1, Pu.1*) were expressed at similar levels in tumors compared to controls ([Figure 5b](#F5){ref-type="fig"}, [Supplementary Figure 5](#SD5){ref-type="supplementary-material"}).

*PRDM14* is overexpressed in a subset of human ALLs {#S7}
---------------------------------------------------

We next determined the degree and frequency and levels of *PRDM14* expression in human ALL. Outlier analyses of microarray gene expression data from multiple previous studies of pediatric ALL showed that the levels of *PRDM14* expression in a subset of 10--25% of patients placed *PRDM14* among the top 1--2% of most overexpressed of all genes in these cohorts ([@R4], [@R38], [@R55], [@R59]). In one study of 132 patients, in which cytogenetic abnormalities and histology were available, overexpression of *PRDM14* was associated most frequently with high hyperdiploid (chromosome number greater than 50) tumors as well as T-ALL ([Figure 6a](#F6){ref-type="fig"}) ([@R55]).

In light of these findings, we examined *PRDM14* expression levels in primary tumor samples from patients with high hyperdiploid ALL and T-ALL. Preliminary analysis of 24 samples confirmed *PRDM14* expression in 9/12 (75%) of high hyperdiploid pre-B ALLs and 7/12 (58%) of T-ALL samples ([Figure 6b](#F6){ref-type="fig"}). Although the levels of *PRDM14* expression were low relative to expression levels of reference genes (data not shown), the transcript levels in *PRDM14*-expressing samples were at least 50-fold greater than the lowest levels detectable by our assay ([Figure 6b](#F6){ref-type="fig"}). Comparisons of *PRDM14* transcript levels with those of other pluripotency genes demonstrated statistically significant overexpression of *POU5F1* (*OCT4*) in *PRDM14*-expressing T-ALL samples ([Figure 6c](#F6){ref-type="fig"}; [Supplementary Figure 6](#SD6){ref-type="supplementary-material"}).

Discussion {#S8}
==========

Here we show for the first time that *Prdm14* acts as a proto-oncogene *in vivo*. Overexpression of *Prdm14* via retroviral transduction of mouse BM cells used to reconstitute lethally irradiated mice resulted in the development of LLs. Interestingly, the incidence of disease in female mice (96%) was more than twice that in male mice (42%). The onset of LL was preceded by a marked expansion of cells with the immunophenotype of CLPs. Both pre-leukemic cells and LLs from *Prdm14* recipients expressed a series of pluripotency markers and oncogenes at high levels. Additionally, we detected overexpression of *PRDM14* in the majority of high hyperdiploid and T-ALL samples, both in analyses of previously published array data as well as in our own analysis of primary patient samples. Significantly, little or no *PRDM14* expression has been previously detected in normal mouse or human tissues other than in pluripotent cells ([@R11], [@R47], [@R61], [@R65], [@R68]). Combined with our leukemogenic mouse model, our discovery of *PRDM14* expression in human leukemias suggests a novel mechanism of cancer initiation and possibly tumor progression in human hematopoietic malignancies.

Importantly, we have shown that a PR domain-containing protein can initiate cancer. Usually, isoforms of genes that contain a PR domain act as tumor suppressors *in vivo*. Even though Prdm1 functions in a signaling cascade with Prdm14 in establishing pluripotency in primordial germ cell (PGC) development ([@R48]), PRDM1 functions as a tumor suppressor in DLBCLs ([@R51]). Perhaps the differences between Prdm14 and Prdm1 in cancer are related to their normal functions in PGC development: Prdm1 represses somatic cell gene transcription in PGCs, while Prdm14 is essential for epigenetic reprogramming events required to establish the pluripotency of nascent PGCs ([@R68]). The high ratio of upregulated to downregulated genes in our gene expression array analyses also suggests that Prdm14 functions in transcriptional activation, unlike other PR-domain containing proteins, which primarily function as transcriptional repressors. Our expression data are consistent with expression profiles of human ES cells depleted of PRDM14 ([@R7]).

*Prdm14* acts as a proto-oncogene by interfering with normal hematopoietic development. Despite levels of engraftment similar to those of EV-transduced marrow cells at four weeks post reconstitution, *Prdm14*-expressing marrow cells contributed a smaller fraction of PB cells. By twelve weeks post reconstitution, engraftment of *Prdm14*-transduced cells had declined, and the contribution of *Prdm14*-expressing cells to T-cell, myeloid cell, and erythrocytic lineages was negligible. While these findings could suggest innately impaired engraftment potential due to *Prdm14* expression, it is more likely that they simply reflect the skewed cellular differentiation that occurs in *Prdm14*-transduced marrow. Most significantly, marrow populations of IL7R^+^lin^−^ early lymphoid progenitors, especially CLP-like cells, were dramatically increased at four weeks over baseline. By twelve weeks, the frequency of these IL-7Rα^+^lin^−^Kit^+^Sca1^+^ cells started to decline. However, a concomitant expansion of B-lineage cells and developmental arrest at the pro-B cell stage both suggest that a fraction of these cells attempted but failed to complete B-cell differentiation. Gene expression analysis of pre-leukemic cells was consistent with this block, with upregulation of genes associated with commitment to the B-lineage (*Tcf3, Il7r*) and downregulation of genes associated with B-cell maturation and activation (*Cd27, Lat2, Blnk*). Despite waning overall engraftment of transduced cells, 80% of *Prdm14* recipients eventually developed a spectrum of clonal, GFP-expressing LLs arrested at varying stages of lymphoid development including pre-pro-B, pro-B, precursor T, and even CLP. This diversity of tumors suggests that the expansion of a hardy immature lymphoid population derived from *Prdm14*-transduced cells led directly to the development of leukemias in these mice.

Epigenetic events that would normally lead to a pluripotent state in germ cells seem to be perturbed in cells aberrantly expressing *Prdm14*, resulting in expanded populations of stem-like progenitor cells. Although global epigenetic changes were not observed in *Prdm14*-expressing tumors (data not shown), the ZFs in PR domain proteins target the protein to specific DNA sequences ([@R7], [@R45]). *Prdm14*-expressing pre-leukemic cells overexpressed genes at imprinted loci, including *H19*, *Odz4*, *Dlk1*, and *Meg3. Dlk1* and *Meg3* are encoded within a complex locus, *Dlk1-Dio3*, which regulates the pluripotency of mouse ES cells and iPS cells ([@R36], [@R60]). Differentially methylated regions (DMR) throughout the locus regulate reciprocal imprinting of *Dlk1* and adjacent non-coding RNAs including *Meg3*. In human disease, abnormal methylation at *DLK1* correlates with biallelic overexpression in 61% of acute myelogenous leukemias ([@R29]). Further, *DLK1* overexpression is associated with myelodysplastic syndrome as well as megakaryocytic and erythroleukemias ([@R56]). Given that Prdm14 resets the epigenetic programming of PGCs, the overexpression of imprinted genes in our tumors indicates that genes or long non-coding RNAs within loci such as *Dlk1-Dio3* may be targets of Prdm14 in resetting pluripotency. Surprisingly, *Prdm14* overexpression induced upregulation of the early embryonic histone methyltransferase Glp. Glp is also upregulated in *Prdm14*^−/−^ mice, leading the authors to conclude that Prdm14 directly inhibits Glp ([@R68]). However, our finding may reflect a more complex regulatory scheme for expression of Glp.

Based on our gene expression profiling of the pre-leukemic population, Prdm14 triggered a cascade of altered gene expression induced via multiple pathways involved in oncogenesis ([Figure 7a](#F7){ref-type="fig"}). Upregulation of genes involved in the EMT suggests a phenotype of cancer stem cell activation, tumor invasiveness, increased metastasis, and increased drug resistance ([@R23], [@R58]). Self-renewal pathways (Wnt, Ras, AKT) exhibited altered expression of pathway initiators (i.e. Hhex, Tcf3) and mediators (i.e. Mtor) suggestive of partial constitutive pathway activation. Notably, stem cell markers such as *Kit* and *Myc* were overexpressed in tumors compared to normal spleen, but had the same expression levels as in bone marrow, reflective of stem cell-like characteristics in mature tumors. These genes are associated with both PGC development and a stem cell phenotype in human leukemias and breast cancers ([@R3], [@R33], [@R49], [@R64]).

Although pre-leukemic cell populations expanded soon after transplantation, Prdm14-transduced mice exhibited an extended latent period prior to developing leukemia. Activation of the p53 pathway and the pro-apoptotic Bcl-family genes *Bax* and *Bbc3* (*PUMA*) may prevent the rapid development of tumors ([Figure 7a](#F7){ref-type="fig"}). Unlike the pre-leukemic cells, however, mature tumors exhibited further gene expression changes that likely overwhelm normal anti-proliferative controls. Eventual overexpression of *Pou5f1* and *Prdm1* in mature tumors, in combination with previously expressed genes from the *Dlk1-Dio3* locus, point to a powerful trend toward pluripotent drive independent of *Sox2* and *Nanog* expression. *POU5F1* overexpression in both mouse LLs and human T-ALL with *PRDM14* overexpression suggests activation of pluripotency as a means of self-renewal. *Prdm14*-induced LLs also expressed Myb at high levels, both as transcript and protein. Myb induces increased self-renewal of hematopoietic cells and is required for the up-regulation of many lymphoid-associated genes, including *Il7r*, as well as for the earliest stages of lymphoid commitment in lymphoid primed progenitors ([@R17], [@R54]). Given the essential role of Myb in the development of the CLP population ([@R17]), eventual expansion of and tumor evolution from our abnormal CLP-like cells may well be triggered once Myb expression increases. *MYB* is also highly expressed in estrogen receptor-positive breast cancer cells, and its transcription is activated when estradiol binds estrogen receptor alpha ([@R13], [@R18]). The linkage between estrogen and levels of *Myb* expression may help explain the higher frequency of *Prdm14*-induced LLs in female than in male mice observed in this study.

Identification of cells with cancer-initiating properties has become a driving force in tumor biology. It has been hypothesized that stem cells with the ability to self-renew, a process by which cells maintain the ability to undergo extensive proliferation while preserving the undifferentiated state, lie at the origins of all cancers with tumors developing from maturational arrest of tissue-specific stem cells. The results of the current study outline a model of an ancestral, pre-leukemic clone in the mouse from a population of IL-7Rα^+^lin^−^Kit^+^Sca1^+^ lymphoid progenitor cells with impaired ability to complete maturation. Evolution from an apparent ancestral clone has been demonstrated in childhood ALL in multiple analyses of paired diagnosis and relapse samples, in which tumors from a subset of patients lost some chromosomal abnormalities at relapse, while other abnormalities were retained ([@R8], [@R9], [@R14], [@R43]). We therefore propose a model for the development of PRDM14-expressing lymphoid leukemias: an initiating mutation in a susceptible progenitor cell perturbs its self-renewal or differentiation to expand a pool of leukemia-initiating cells (L-ICs), which initially proliferate slowly ([Figure 7b](#F7){ref-type="fig"}). The L-ICs attempt but fail to complete the developmental program, which then goes awry ([@R6], [@R28], [@R63]). In human disease, these persistent and abnormal L-IC clones could resist therapy simply due to their indolent state, with their propensity to self-renew and acquire new mutations leading to subsequent malignant retransformation and disease relapse.

Although LLs arise from an expanded progenitor pool in our mouse model of *Prdm14*-induced leukemogenesis, *PRDM14* may be a cancer stem cell oncogene that is dependent on the cellular milieu in which it is expressed to trigger cancer. For instance, *PRDM14* is overexpressed in a large proportion of human breast cancers as a result of gene amplification and in association with aberrant CpG methylation of the second intron ([@R24], [@R47]). If PRDM14 acts similarly in breast tissue and in hematopoietic cells, it may activate a pluripotency cascade in differentiated cells that leads to the development of self-renewing, de-differentiated, pre-cancerous clones, if not a "cancer stem cell" ([@R66]). We conclude that in light of its broad relevance to cancer initiation, as well as its limited expression in normal tissues, PRDM14 and its regulatory targets are likely to provide prime candidates for therapeutic interventions in cancer.

Materials and Methods {#S9}
=====================

Animal care {#S10}
-----------

All mouse experiments were carried out under the approval of the Institutional Animal Care and Use Committee at Baylor College of Medicine (BCM). Mice were housed in the barrier facility at BCM, under the care of the Center for Comparative Medicine, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.

Human samples {#S11}
-------------

Patient samples were obtained between 1996 and 2004 through an institutional review board-approved protocol (Molecular Characterization of Normal and Abnormal Hematopoiesis, H3342) at Texas Children's Hospital (Houston, TX) after informed consent was obtained. Samples from PB via venipuncture or leukopheresis, or from BM via aspiration, were lysed in Ultraspec RNA reagent (Biotecx, Houston, TX) for long-term storage.

Molecular cloning of *Prdm14* {#S12}
-----------------------------

The coding sequence of *Prdm14* was amplified using Platinum Pfx (Invitrogen, Carlsbad, CA) using cDNA isolated from the *Evi32* insertion-containing tumor, 27-001, and subcloned into the MIGR1 vector, a gift from Robert Hawley ([@R21]) using *Xho*I restriction enzyme sites designed in the primer sequences. The murine stem cell virus-based vector was chosen due to its known efficiency in infecting hematopoietic stem cells (HSCs) ([@R52], [@R57], [@R69]). The recombinant virus was sequenced to verify integrity and orientation.

Retroviral transductions {#S13}
------------------------

Retroviral supernatants were produced via transient transfection of 293T cells with the *Prdm14*-MIGR1 vector or a MIGR1-EV along with the PCL-Eco packaging construct using Lipofectamine 2000 (Invitrogen) ([@R46]). Retrovirus-containing supernatants were collected 48 hours post-transfection and were titered by infection of NIH3T3 fibroblasts followed by flow cytometric analyses to determine percentages of GFP-positive cells. Donor C57BL/6J-CD45.2 mice were injected intraperitoneally with 150 mg/kg of 5-FU. The mice were killed six days later, and total BM cells were isolated. Donor BM cells were incubated in Stempro 34 media (Invitrogen) containing 6 ng/ml IL-3, 10 ng/ml IL-6, and 100 ng/ml stem cell factor (SCF) (Peprotech, Rocky Hill, NJ). Polybrene was added to the media at a final concentration of 4 μg/mL, and retroviral supernatants were added to the cells at a MOI of one. Cells were spin-infected at 1266xg for two hours at room temperature. Sex-matched recipient C57BL/6J-CD45.1 mice given a split dose of 11 gray of γ-irradiation were injected via the retro-orbital sinus with 10^5^ BM cells. Control mice were subjected to irradiation to ensure lethal levels. Irradiated mice were monitored daily for signs of morbidity.

Flow cytometry {#S14}
--------------

Flow cytometry was carried out on PB and on cell suspensions prepared from tumors, BM, spleen, and thymus. PB was collected from the retro-orbital sinus followed by treatment with ammonium-chloride lysing buffer to remove red blood cells. Cells were stained with cocktails of fluorescently-labeled antibodies for lineage (CD45.2, B220, CD4, CD8, Mac1, and Gr1), for B-cell development (CD19, CD43, IgM, and B220), for late T-cell development (CD3, CD4, and CD8), for early T-cell development (CD25, CD44, CD4, and CD8), for CLP (IL7-Rα, Kit, Sca-1, CD4, CD8, CD3, B220, Ter119, Mac1, and Gr1), or for erythroid and natural killer (NK) cells (Ter119 and NK1.1) (BD Biosciences, San Jose, CA; eBiosciences, San Diego, CA). Nucleated cells were gated based on forward scatter (FSC) and side scatter (SSC), with propidium iodide (PI) staining used to exclude dead cells. Cells were analyzed using a four laser BD Special Order LSR-II (BD Biosciences). FlowJo Software was used for data analyses (Tree Star Inc., Ashland, OR).

Gene expression analysis {#S15}
------------------------

RNA was extracted, and cDNA generated, according to standard protocols ([Supplementary Methods](#SD1){ref-type="supplementary-material"}). Quantitative reverse transcription polymerase chain reaction (qPCR) was carried out in triplicate using the ABI Prism 7000 Sequence Detection System and ABI 7900HT Fast Real Time PCR system (Applied Biosystems \[ABI\], Carlsbad, CA). Gene expression studies were conducted with SybrGreen Master Mix (ABI) and custom primers ([Supplementary Table 2](#SD9){ref-type="supplementary-material"}), designed using Primer Express 3.0 (ABI) and RealTime PCR design tool (Integrated DNA Technologies, Coralville, IA). Human *PRDM14* expression was determined using TaqMan gene expression assay Hs01119055_m1 with Gene Expression Master Mix (ABI). PCR and fold change analysis were performed as described previously ([@R11]). *GAPDH* and 18S rRNA served as reference genes in mouse tissue; *TBP* (ABI assay 4326322E) was used as the reference in human tissue ([@R37]).

Gene expression microarray {#S16}
--------------------------

30,000 IL-7Ra^+^lin^−^Kit^+^Sca1^+^ cells were sorted from whole bone marrow obtained from *Prdm14*-transduced and EV-transduced mice four weeks post transplantation using BD FACSAira II (BD Biosciences), with \>92% post-sort cell purity. Total RNA was obtained using RNAqueous Micro (Ambion). RNA quality was assessed with the Experion bioanalyzer using the Stdsens Chip (BioRad, Hercules, CA). RNA samples were amplified with in vitro transcription using the Illumina TotalPrep RNA Amplification kit (Ambion). RNA was then labeled and hybridized to MouseWG-6 v2.0 Expression BeadChip arrays (Illumina, San Diego, CA). Data was normalized using variance-stabilizing transformation, robust spine normalization. Quality control ([Supplementary Figure 4](#SD4){ref-type="supplementary-material"}), hybridization, and data generation were performed by the Laboratory for Translational Genomics at BCM. Data were analyzed by R ([www.r-project.org](www.r-project.org)) and visualized in Genespring (Agilent, Santa Clara, CA). Gene ontology and pathway analysis was performed with the Database for Annotation, Visualization, and Integrated Discovery at <http://david.abcc.ncifcrf.gov> ([@R10], [@R25]).

Histology/Pathology {#S17}
-------------------

Tumors were fixed using 10% aqueous buffered zinc formalin overnight at room temperature. Samples were dehydrated in ethanol and embedded in paraffin. Tumors were stained with hematoxylin and eosin (Sigma-Aldrich, St. Louis, MO) and analyzed according to established parameters in mouse tumor identification ([@R15], [@R40]).

Western analysis {#S18}
----------------

Western blots were performed using protein extracts from homogenized tumor cells and sorted cells, as previously described ([@R5]). Antibodies directed against actin and Myb were obtained commercially (Santa Cruz Biotechnology, Santa Cruz, CA).

Statistical analysis {#S19}
--------------------

Publicly available expression data from four pediatric ALL studies ([@R4], [@R38], [@R55], [@R59]) were evaluated for *PRDM14* expression levels. Outlier analysis was conducted at the 75th, 90th, and 95^th^ percentiles of expression levels to evaluate for presence of a subset of tumors overexpressing *PRDM14*. Oncomine^™^ (Compendia Bioscience, Ann Arbor, MI) was used for analysis and visualization.

Comparative analysis of gene expression fold change was performed with DataAssist v2.0 (ABI) and Prism v5.0 (GraphPad, La Jolla, CA). Mann-Whitney tests were used to compare relative gene expression levels; error bars represent the median with interquartile range. Logrank analysis of overall survival was performed using Prism v5.0.
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![Overexpression of *Prdm14 in vivo*\
**1a)** Murine stem cell virus vectors were used to overexpress *Prdm14* and serve as an empty vector control. Both vectors contain an IRES sequence and express GFP as a marker of transduced cells. **1b)** An overview shows the experimental method used to express *Prdm14 in vivo*. Mice expressing the CD45.2 cell surface antigen are treated with 5-fluorouracil (5-FU) to induce cycling and enrichment of BM hematopoietic stem cells (HSCs). These CD45.2 donor cells are transduced with retroviral particles containing either *Prdm14*-MIGR1 or the EV-MIGR1 control and then injected intravenously into lethally irradiated recipient mice that express the CD45.1 allele. Engraftment of transduced cells allows for long-term overexpression of *Prdm14*. **1c)** Northern blot analysis of transcripts produced from NIH3T3 cells transduced with *Prdm14*-MIGR1 or the control vector. A GFP probe detects both constructs and shows a higher level of expression in cells transduced with the control vector than with the *Prdm14*-MIGR1 vector. A second probe detects the *Prdm14* transcript only. Both vectors produce transcripts of the expected sizes, shown as arrowheads. **1d)** Four weeks after transplantation, fewer GFP+ cells are detected in PB of mice transduced with *Prdm14*-MIGR1 than with the control. A normal CD45.1 mouse has no GFP fluorescence.](nihms262931f1){#F1}

![Aberrant expression of *Prdm14* expands an early lymphoid cell population\
**2a)** Flow cytometry of BM at four weeks post transduction shows skewing of *Prdm14*-expressing cells towards an early lymphoid population of IL-7Rα^+^lin^−^ cells, many of which express intermediate levels of Kit and Sca1, similar to normal CLP. Serial gating of cells was performed as designated by the arrows. **2b)** Relative frequencies of GFP^+^ cells that are IL7Rα^+^Lin^−^ and CLP (IL7R^+^Lin^−^Kit^+^Sca1^+^) are profoundly expanded in *Prdm14* recipients at 4 weeks. **2c,d)** Recapitulation of flow cytometry of BM at twelve weeks post-transplantation demonstrates smaller fraction of early lymphoid progenitors and CLPs in Prdm14 recipients than at four weeks, but still markedly increased compared to EV recipients. **2e)** BM and PB cells underwent flow cytometry for B220^+^ elements of the B cell lineage at 4, 8, and 12 weeks. GFP^+^ PB cells from *Prdm14* recipients were skewed towards the B cell lineage at all time points compared to cells from EV recipients. GFP^+^ BM cells were not committed to the B cell lineage at four weeks compared to EV BM cells but later appear to skew towards the B cell lineage (but not significantly) at twelve weeks after transplantation. **2f)** Flow cytometry was carried out on BM cells from transduced mice at successive time points after transplantation using early B cell lineage markers (B220, CD43, CD19, and IgM). At twelve weeks after transplantation, cells accumulate at the pro-B stage, but differentiation past this point is markedly limited (Pre-Pro-B B220^+^CD43^+^CD19^−^IgM^−^, Pro-B B220^+^CD43^+^CD19^+^IgM^−^, Pre-B B220^+^CD43^−^CD19^+^IgM^−^, Immature B B220^+^CD43^−^CD19^+^IgM^+^). (\* indicates p\<0.05, \*\* indicates p\<0.01, and \*\*\* indicates p\<0.001).](nihms262931f2){#F2}

![Overexpression of *Prdm14 in vivo* causes LL\
**3a)** The survival of *Prdm14* recipients is significantly reduced compared to EV recipient mice (p\<0.00001). Moribund mice were first observed at approximately 100 days post-transplantation and necropsied as they became ill during the one year aging study. Female mice succumbed to disease more readily than male mice. **3b)** All mice diagnosed as leukemic at least two or more of the following characteristics: splenomegaly (92%), lymphocytosis (46%), thymic enlargement (22%), lymphadenopathy (44%) or hepatic infiltration (44%). *Prdm14* recipients ("Prdm14-MIGR unaffected") that did not develop overt leukemia did not develop these symptoms at a significant rate. **3c)** *Prdm14* was overexpressed in most of the tumors as assessed by quantitative real time PCR. **3d)** Histologic features of LL in *Prdm14* recipients. Left panel: Spleen section with lymphoblasts containing nuclei with central prominent nucleoli interspersed among tingible body macrophages (horizontal arrows), apoptotic cells (vertical arrows), and histiocytes. There are several mitotic figures (arrowheads). Right panel:Section of a thymic mass showing a uniform population of lymphoblasts. There are several large tingible body macrophages with ingested apoptotic debris.](nihms262931f3){#F3}

![*Prdm14* overexpression causes a range of lymphoid leukemia cell types\
**4a)** B220^+^ B-cell tumors were isolated from *Prdm14* transplanted mice. Here, transduced cells are overtaking the BM, with 96% and 71% GFP^+^ cells in the BM in the examples. Tumors were found at the pre-pro-B stage (B220+CD43+CD19−) and the pro-B cell stage (B220+CD43+CD19+IgM−). **4b)** T-cell leukemias also occurred in *Prdm14* recipients. BM and thymus show a high percentage of GFP^+^ cells (57% in thymus and 43% in the bone marrow). These cells are CD4^+^CD8^+^ Double Positive (DP) T-cells, which are normally very rare in the BM of mice. **4c)** *Prdm14* transduction also caused CLP-like tumors. Again, GFP^+^ cells are overtaking the bone marrow, with 91% being GFP^+^. The cells were lin^−^, IL-7Rα^+^, Kit^+^, with intermediate levels of Sca1, similar to the immunophenotype of normal CLPs.](nihms262931f4){#F4}

![*Prdm14* alters expression of pluripotency genes and oncogenes in pre-leukemic and leukemic cells\
**5a)** Heatmap of gene expression in flow-sorted CLP-like cells obtained at four weeks post transplantation from *Prdm14*-transduced and EV-transduced mice. Each column represents one sample. Genes depicted are relevant in oncogenesis, tumor suppression, pluripotency, signal transduction, or B cell development. **5b)** Expression of *Pou5f1*, *Prdm1*, *Dlk1*, *Meg3*, *Mtor*, *Il7r*, *Myb*, *Scin*, and *Glp* is increased in tumors from *Prdm14*-transduced mice. *Sox2* is downregulated. Levels in tumors are compared to both wild-type whole bone marrow and spleen from EV recipients using Mann-Whitney analysis. Error bars represent median with interquartile range (\* indicates p\<0.05 and \*\* indicates p\<0.01). **5c)** Western blot analysis shows increased MYB protein in *Prdm14-*induced leukemias, which is seen neither in EV controls nor in pre-leukemic cells. C = 8 week old spleen control; Prdm14 Pre-LL = spleen from a *Prdm14* recipient that had not developed a tumor.](nihms262931f5){#F5}

![*PRDM14* is overexpressed in a subset of pediatric ALL samples\
**6a)** *PRDM14* relative expression was evaluated in 132 pediatric ALL samples ([@R55]) using Affymetrix Human Genome U133A arrays, normalized to median-centered fluorescence intensity. Samples were sorted by cytogenetics and histologic subtype. Line marked "75^th^ %ile" denotes the 75^th^ percentile of fluorescence intensity within this cohort; samples with expression intensity above this line were compared to samples below for outlier analysis of relative degree of overexpression. **6b)** *PRDM14* relative expression determined by qPCR using TaqMan gene expression assays. Expression normalized to tata-box binding protein (*TBP*); fold change compared to Jurkat cell line. Error bars represent 95% confidence interval of replicates. **6c)** In T-ALL, *POU5F1* expression is increased in samples expressing Prdm14. Other genes evaluated showed no significant difference, although *mTOR* expression trended higher in the *PRDM14*-expressing group. Error bars represent median with interquartile range (\* indicates p\<0.05).](nihms262931f6){#F6}

![A model for the development of lymphoblastic leukemia\
**7a)** Schematic of dyregulated pathways induced by Prdm14 overexpression. **7b)** Overexpression of *PRDM14* initiates leukemia by expanding a progenitor cell pool after its misexpression in hematopoietic stem cells. This pool of leukemia-initiating cells (L-ICs) has an immunophenotype and developmental capacity that is similar to the CLP. Other cells may also be expanded, including multipotential progenitors (MPPs), lymphoid primed multipotential progenitors (LMPPs), early lymphoid progenitors (ELPs), pre-pro B or pro-B cells. Development of these pools occurs as clones are expanded. Most clones likely undergo apoptosis (black), but a rare subclone, expressing GFP, acquires transformed properties with the expression of *Pou5f1*, *Mtor*, and *Myb*.](nihms262931f7){#F7}
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